Role of Superconducting Materials in the Endeavor to Stop Climate Change and Reach Sustainable Development.

Progress in the mass production of newly developed bulk (Gd0.33Y0.13Er0.53)Ba2Cu3Oy "(Gd,Y,Er)123" and MgB2 systems is presented. Two batches of (Gd,Y,Er)123 pellets of 20 mm diameter and 7 mm thick were prepared in air by an infiltration growth "IG" process. Trapped field distribution profiles of fully grown bulk samples clearly showed that all samples were single-grain and the trapped field values were more than 0.5 T at 77 K, 1.3 mm above top surface. The best bulk exhibited the trapped field value of 0.63 T at 77 K. Ultra-sonication technique was employed for refining precursors of both (Gd,Y,Er)211 and boron. TEM studies revealed that boron powder subjected to ultrasonication was refined up to nanoscale. The micron-sized particles were reduced to nanoscale, which led to improvement of critical current by up to 36% in bulk MgB2 at 20 K and self-field. This progress in fabrication of high-performance LREBa2Cu3Oy and MgB2 superconducting bulks further promotes commercialization of superconductors' production as a mode of sustainable technology.

Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design.

PURPOSE: To investigate the anatomy of the pelvis following robotic-assisted radical prostatectomy (RARP) compared to the anatomy of the pelvis following open prostatectomy (OP), and to determine if postoperative radiation field design should take surgical approach into consideration. METHODS AND MATERIALS: This report is a retrospective review of the postoperative pelvic magnetic resonance imaging (MRI) scans for all OP patients (10) and all RARP patients (15) who presented consecutively to the radiation oncology clinic and subsequently underwent MRI scanning between January 2007 and December 2008. All patients who presented are included in the study. We measured 13 distinct anatomic distances, and we used t tests to examine mean differences in each of the parameters between RARP and OP and analysis of variance to examine mean differences controlling for length of follow-up MRI postsurgery (in days) and body mass index as covariates. RESULTS: Of the measurements, we found that the superior levator separation is statistically significantly greater in the post-RARP group than in the post-OP group (P < .01). Similarly, the post-RARP group had a greater mean resection defect measurement (P = .01) as measured by a larger width of the bladder infundibulum. This suggests that the size of trigonal musculature defect is more pronounced after RARP. The total urethral length was statistically significantly longer in the RARP group (P = .03). The vesicorectal distance was variable depending on the location along the rectal wall but trended toward larger separation in the post-RARP group (P = .05). CONCLUSIONS: The pelvic anatomy after RARP is considerably different from that after OP. The current standard field design for post-prostatectomy radiation is defined by the post-OP pelvis. Our data support that the clinical target volume borders be expanded posteriorly and laterally in men who have undergone RARP. As RARP continues to become a more widespread surgical option for the management of localized prostate cancer, radiation field design may need to be adjusted.

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

PURPOSE: To perform a phase I trial of recombinant human endostatin (rhEndostatin; EntreMed, Rockville, MD) given as a daily 20-minute intravenous (IV) injection in adult patients with refractory solid tumors. PATIENTS AND METHODS: The daily dose was increased from 15 to 240 mg/m(2) by a factor of 100% in cohorts of three patients. In the absence of dose-limiting toxicity, uninterrupted treatment was continued until the tumor burden increased by more than 50% from baseline. Correlative studies included dynamic contrast-enhanced magnetic resonance imaging of tumor blood flow, urinary vascular endothelial growth factor and basic fibroblast growth factor levels, rhEndostatin serum pharmacokinetics, and monitoring of circulating antibodies to rhEndostatin. RESULTS: There were no notable treatment related toxicities among 15 patients receiving a total of 50 monthly cycles of rhEndostatin. One patient with a pancreatic neuroendocrine tumor had a minor response and two patients showed disease stabilization. Linearity in the pharmacokinetics of rhEndostatin was indicated by dose-proportionate increases in the area under the curve for the first dose and the peak serum concentration at steady state. Daily systemic exposure to rhEndostatin in patients receiving 240 mg/m(2)/d was approximately 50% lower than that provided by the therapeutically optimal dose in preclinical studies. CONCLUSION: rhEndostatin administered as a 20-minute daily IV injection at doses up to 240 mg/m(2) showed no significant toxicities. Evidence of clinical benefit was observed in three patients. Due to high variability between the peak and trough serum concentrations associated with the repeated short IV infusion schedule, daily serum drug levels only briefly exceeded concentrations necessary for in vitro antiangiogenic effects.

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.

PURPOSE: To evaluate the efficacy of rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) induction therapy in patients with newly diagnosed mantle-cell lymphoma (MCL). PATIENTS AND METHODS: From March 1997 to May 1999, 40 previously untreated patients with stage II through IV MCL were treated with six cycles of rituximab and CHOP chemotherapy in a phase II trial. Pretreatment and interval peripheral-blood (PB) and bone marrow (BM) specimens were also analyzed by polymerase chain reaction (PCR) for tumor-specific BCL-1/immunoglobulin H (IgH) translocations and clonal IgH rearrangements. Study end points included clinical and molecular response rates and long-term progression-free survival (PFS). RESULTS: Forty-eight percent of patients achieved a complete response (CR)/CR unconfirmed (CRu), and 48% of patients obtained a partial response (PR). However, 28 of the 40 patients have already relapsed or developed progressive disease with a median PFS of 16.6 months. Twenty-five patients had PCR-detectable BCL-1/IgH or clonal IgH products in PB or BM at diagnosis. Nine of the 25 informative patients had no evidence of PCR-detectable disease in PB or BM after rituximab and CHOP therapy. However, patients who achieved molecular remissions in PB or BM had PFS similar to patients without molecular remissions (16.5 v 18.8 months, P =.51). CONCLUSION: Favorable clinical and molecular response rates associated with rituximab and CHOP chemotherapy do not translate into prolonged PFS in MCL. Nevertheless, rituximab and combination chemotherapy may transiently clear PB or BM of detectable tumor cells, prompting additional consideration of antibody-based in vivo purging in subsequent clinical trials.

Dynamics of pigment pattern formation in the zebrafish, Brachydanio rerio. III. Effect of anteroposterior location of three-day lateral line melanophores on colonization by the second wave of melanophores.

The mode of colonization of the lateral line melanophore band of the zebrafish, Brachydanio rerio, by the second wave of melanophores has been investigated. This stripe forms in two consecutive stages. First, there is an initial migration and reorientation of pigment cells in an anteroposterior wave into the site to form an interrupted stripe. Following this, a round of melanophores differentiates directly at the site and fills in the gaps between the initial cells. An analysis of the distributions of initial and second wave melanophores along the stripe site has shown that both groups of cells are selective as to localization. Initial wave melanophores colonize more anterior somite areas than do second wave melanophores. However, both groups of cells exhibit preferential colonization of the same anterior sites. It is suggested that second wave melanophores attempt to colonize the same somite areas of the stripe as the initial wave of melanophores but are forced to move to more posterior locations due to the presence of initial wave melanophores anteriorly. Observations were also made on later stages of development of the lateral line melanophore band. These melanophores retain the ability to migrate. Some of them reorient out onto the flank and contribute to the juvenile flank pigment pattern.